<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Despite development in therapeutic strategies, such as neoadjuvant concurrent chemoradiotherapy (CCRT), the prognosis of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> remains relatively poor </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> stem cells (<z:chebi fb="11" ids="17437,53115">CSC</z:chebi>) with several characteristics can lead to therapeutic resistance </plain></SENT>
<SENT sid="2" pm="."><plain>CD133 has been identified as a putative <z:chebi fb="11" ids="17437,53115">CSC</z:chebi> marker in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>; however, its functional role still needs elucidation </plain></SENT>
<SENT sid="3" pm="."><plain>We verified the role of CD133 with emphasis on expression location and correlated the results of CD133 with clinical outcome in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: We used immunohistochemistry to investigate the expression of CD133 in samples from 157 patients with <z:mp ids='MP_0009314'>colonic adenocarcinoma</z:mp> and from 76 patients with <z:mp ids='MP_0009315'>rectal adenocarcinoma</z:mp> who received neoadjuvant CCRT </plain></SENT>
<SENT sid="5" pm="."><plain>We also correlated the expression location of CD133 with the clinicopathological parameters and prognosis </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: CD133 protein was variably overexpressed in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> tissues and was present in three locations: apical and/or endoluminal surfaces, cytoplasm, and lumen </plain></SENT>
<SENT sid="7" pm="."><plain>Cytoplasmic CD133 expression level correlated significantly with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> local recurrence (P = 0.025) and survival of patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (P = 0.002), and correlated inversely with <z:mp ids='MP_0010537'>tumor regression</z:mp> grading (P = 0.021) after CCRT in patients with <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: The expression of CD133 in the cytoplasm is closely associated with local recurrence and patient survival, and may provide a reliable prognostic indicator of <z:mp ids='MP_0010537'>tumor regression</z:mp> grading in patients with <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> after CCRT </plain></SENT>
<SENT sid="9" pm="."><plain>Cytoplasmic CD133 expression may also help identify the surviving <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells in areas with nearly total regression after CCRT </plain></SENT>
</text></document>